Healthcare Industry News: ELIQUIS
News Release - December 29, 2012
Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS(R) (apixaban)
PRINCETON, N.J. & NEW YORK--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved ELIQUIS® (apixaban).Please see full Prescribing Information including BOXED WARNING and Medication Guide available at www.bms.com.
Bristol-Myers Squibb and Pfizer will provide additional information on the FDA approval of ELIQUIS in a separate press release, to be issued next week.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
